Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Immunomedics (IMMU) - moderated -- Ignore unavailable to you. Want to Upgrade?

To: idahoranch1 who wrote (38487)	1/6/2017 11:35:02 PM
From: stockdoc77	Read Replies (1) \| Respond to of 63291

As a shareholder, there is a strong argument that changing management is in our best interest. Getting rid of the Goldenberg discount should in theory push our stock much higher, a prospect that I certainly look forward to. My point is that from Venbio's perspective, taking control of the company, at least based on the call, is all about determining the path forward for 132. They are not interested in IMMU for the rest of the pipeline, and assigned little or no significance to it. But if a partnership is announced, then IMMU no longer controls 132, the partner does. So controlling IMMU at that point serves no purpose from Venbio's position, as the further development of 132 will be entirely up to the partner. It may be that changing the board still helps us get a higher stock price, and that is great, but it has nothing to do with future development of 132.